Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma.

Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC. Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup. These f

Trial Details

NCT ID
NCT07937553
Phase
PHASE2
Sponsor
Kidney Cancer Research Bureau
Status
RECRUITING
Cancer Type
Clear Cell Renal Cell Carcinoma Kidney Cancer
Interventions
  • Lenvatinib
  • Pembolizumab
  • everolimus
Locations (sample)
  • Chelyabinsk, Russia|55.1611,61.42877
  • Krasnoyarsk, Russia|56.03742,92.93136
  • Orenburg, Russia|51.76712,55.09883
  • Saint Petersburg, Russia|59.93863,30.31413
  • Saint Petersburg, Russia|59.93863,30.31413

Key Eligibility Criteria

  • Histologically confirmed chromophobe renal cell carcinoma.
  • Measurable disease according to RECIST version 1.1.
  • ECOG performance status of 0-3.
  • Cohort A: No prior systemic therapy for metastatic disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Clear Cell Renal Cell Carcinoma Kidney Cancer Trials on Trialify →